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Anti-neuronal autoimmune encephalitis (AIE) comprises a recently characterized group of
immune-mediated disorders that result in limbic, multifocal, or diffuse encephalitis due
to direct interaction of autoantibodies with neuronal surface or synaptic proteins. The
pathological effects of the autoantibodies vary according to the target antigen but when
they are removed, neuronal dysfunction is commonly reversed. Ongoing research on AIE
constantly increases the number of novel autoantibodies and expands the spectrum
of neurological syndromes that are important in the differential diagnosis of psychiatric
illness, dementia, or viral encephalitis. This review summarizes recent advances in
AIE, focusing on pathogenetic mechanisms and novel associations with other CNS
disorders such as neurodegeneration, relapsing symptoms post-herpes simplex virus
encephalitis, and demyelinating diseases. In addition, an algorithmic approach to detect
and characterize neuronal cell surface autoantibodies is proposed.
Keywords: autoimmune encephalitis, anti-NMDAR encephalitis, limbic encephalitis, anti-neuronal antibodies,
tissue-based assay
Introduction
Antibody-associated neuronal autoimmune disorders are a heterogenous group of syndromes that
result from an autoimmune reaction to neuronal antigens. These disorders can broadly be divided
into two main groups: classic paraneoplastic neurological syndromes (PNS) that associate with
autoantibodies to intracellular neuronal antigens (e.g., Hu, Yo, Ri) and autoimmune encephalitis
(AIE) that associate with autoantibodies to neuronal surface or synaptic antigens (1). The PNS
typically occur in the context of cancer and almost always affect adults. These disorders result from
an immunological response against tumor antigens that is misdirected to similar antigens expressed
in the CNS. The autoantibodies against intracellular antigens have not been shown to be pathogenic.
Patients with these autoantibodies show limited or no response to immunotherapy. In contrast,
the AIE occur in association with autoantibodies against easily accessible antigens on the neuronal
surface, such as synaptic receptors and membrane antigens [e.g., NMDAR, AMPAR, GABA(B)R]
and the binding of the autoantibodies to their targets directly causes neuronal dysfunction. These
diseasesmainly affect young adults, adolescents, and children but can also occur in older individuals.
The disorders may mimic psychiatric illness, dementia, or viral encephalitis, which often confuses
and delays the diagnosis. Each of the identified autoantibodies associate with either a specific
Abbreviations: AMPAR, amino-3-hydroxy-5-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; ANA, anti-nuclear anti-
bodies; CASPR2, contactin-associated protein-like 2; D2R, dopamine-2 receptor; DPPX, dipeptidyl-peptidase-like protein-6;
dsDNA, double-stranded DNA; GABA A/B R, gamma-aminobutyric acid A/B receptor; GlyR, glycine receptor; LGI1, leucine-
rich glioma-inactivated 1; mGluR1/5, metabotropic glutamate receptor type 1/5; NMDAR, N-methyl--aspartate receptor;
TPO, thyroid peroxidase.
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syndrome or a characteristic repertoire of symptoms and the
detection of these autoantibodies confirms the diagnosis. This is
important as patients with AIE often respond to immunotherapy.
The following sections will give an overview of recent advances
in AIE associated with neuronal cell surface autoantibodies with
emphasis on pathogenesis, clinical presentation, and diagnostic
approach.
Pathogenetic Mechanisms
Most data on pathogenetic mechanisms associated with the
neuronal cell surface autoantibodies focus on the NMDAR-
antibodies found in patients with anti-NMDAR encephalitis.
These autoantibodies recognize an extracellular, conformation-
dependent epitope region close to aminoacid 369 of the GluN1
subunit of the NMDAR. The autoantibodies crosslink and inter-
nalize the NMDAR, which reduces the receptor density on the
neuronal surface resulting in neuronal dysfunction (2). This
process is reversible after removal of autoantibodies and may
explain the good recovery of patients after immunotherapy (3).
The NMDAR-antibodies that are highly specific for anti-NMDAR
encephalitis should be distinguished from other types of gluta-
mate receptor autoantibodies. For example, anti-double-stranded
DNA (dsDNA) antibodies that cross-react with a linear epitope
of the GluN2A and B subunits of the NMDAR have been found
in 30–40% of patients with systemic lupus erythematodes (SLE)
but whether these autoantibodies are responsible for neuropsy-
chiatric symptoms of SLE remains a matter of controversy (4).
Whereas the internalization of receptors was also described as an
effect of autoantibodies found in AMPAR encephalitis (5), other
AIE-associated autoantibodies may work through differentmech-
anisms. For example, GABA(B)R-antibodies influence receptor
function and block the inhibitory effects of baclofen on the spon-
taneous firing of cultured neurons, GABA(A)R-antibodies relo-
cate the receptor from the synaptic to the extrasynaptic site, and
LGI1-antibodies block the binding of LGI1 to ADAM22 that by
unclear mechanisms results in a decrease of the AMPAR (1, 6).
Future studies focusing on the antibody–receptor interaction will
contribute to our understanding of immune mechanisms in AIE
and could lead to more specific therapies in different stages of the
disease.
Clinical Presentation
Each of the currently known neuronal cell surface or synaptic
autoantibodies associates with a specific syndrome or limited
set of symptoms (Table 1). Anti-NMDAR encephalitis usually
develops as a multistage process. Many patients have a prodromal
syndrome and in a few days develop progressive anxiety, agitation,
psychosis, memory deficits, and speech reduction. The disease
then progresses to abnormal movements, coma, hypoventilation,
and autonomic instability. In children, the behavioral change
may be more difficult to detect, often with temper tantrums,
hyperactivity, or irritability and there is a greater tendency for
the first recognized symptom to be non-psychiatric, including
seizures, abnormal movements, verbal reduction, or mutism (1,
3). The encephalitis associated with LGI1-, GABA(B)R-, and
AMPAR-antibodies were originally described as classical limbic
TABLE 1 |Neuronal cell surface autoantibodies, associated tumors, and the
clinical symptoms.
Antigen Tumor Clinical symptoms
NMDAR Ovarian teratoma (58%
in patients >18 years)
Encephalitis
LGI1 Thymoma (<10%) LE, myoclonia, hyponatremia




GABABR SCLC (50%) LE, ataxia
GABAAR – Status epilepticus, seizures,
encephalitis
mGluR1 M. Hodgkin Cerebellar ataxia
mGluR5 M. Hodgkin Ophelia syndrome




IgLON5 – Non-REM and REM-sleep disorder,
brainstem, and limbic dysfunction
GlyR Lung cancer SPS, PERM
Dopamine 2R – Basal ganglia encephalitis,
Sydenham’s Chorea
NMDAR, N-methyl-d-aspartate receptor; LGI1, leucine-rich glioma-inactivated 1;
CASPR2, contactin-associated protein-like 2; AMPAR, amino-3-hydroxy-5-hydroxy-5-
methyl-4-isoxazolepropionic acid receptor; GABA A/B R, gamma-aminobutyric acid
A/B receptor; mGluR1/5, metabotropic glutamate receptor type 1/5; DPPX, dipeptidyl-
peptidase-like protein-6; GlyR, Glycine receptor; CLL, chronic lymphatic leukemia; SCLC,
small cell lung cancer; LE, limbic encephalitis; SPS, stiff-person syndrome; PERM,
progressive encephalomyelitis with rigidity and myoclonus.
encephalitis but additional features might suggest the targeted
antigen. For example, autoantibodies to LGI1 often associate with
hyponatremia but rarely associate with a tumor, GABA(B)R-
antibodies frequently occur with prominent seizures and about
half of the patients have a small cell lung cancer (SCLC),
while patients with AMPAR-antibodies often present with limbic
encephalitis or psychiatric features (1, 5, 7). Some autoantibod-
ies may associate with symptoms that extend beyond the CNS.
For example, the encephalitis associated with DPPX-antibodies
often starts with diarrhea or gastrointestinal dysfunction and
substantial weight loss. This is then followed by the onset of
neuropsychiatric and brainstem symptoms including symptoms
of central nervous system hyperexcitability (seizures, tremulous-
ness, myoclonus, nystagmus, hyperekplexia) (8) or a clinical pic-
ture resembling progressive encephalomyelitis with rigidity and
myoclonus (PERM) (9).
An intriguing relation between autoimmunity and neurode-
generation has recently been discovered with the characterization
of the IgLON5-antibody. These autoantibodies were detected in
patients with prominent rapid-eye movement (REM) and non-
REM-sleep dysfunction with abnormal behavior and movements,
and brainstem symptoms with a chronic (or less frequently suba-
cute) progressive disease course. Autopsy of two patients revealed
deposits of tau that mainly affected neurons of the hypothalamus,
thalamus, and brainstem. Although these findings suggest a link
between IgLON5-antibodies and tau aggregation, it remains to
be elucidated whether the autoantibodies are pathogenic or only
an epiphenomenon (10). With the increased recognition of AIE
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novel associationswith other disorders are emerging that connects
different fields of medicine and emphasizes the importance of




Different techniques are available for the diagnosis of neuronal
cell surface antibodies: tissue-based assays (TBA; in-house or
commercially available), cell-based assay (CBA; in-house or com-
mercially available), primary cultures of neurons (in-house), and
immunoprecipitation (IP; in-house). In the TBA, rat or mouse
brains are stained with CSF or serum of patients with an indirect
immunhistochemistry or immunofluorescence technique. Anti-
neuronal antibodies attach to their receptor or synaptic antigen
in the rodent brain, resulting in a neuropil staining pattern in the
hippocampus. In the CBA, cells (e.g., HEK293 cells) are trans-
fected with the respective surface receptor or synaptic antigen
and stained with CSF or serum of the patients with an indi-
rect immunofluorescence technique. Autoantibodies against the
specifically expressed receptor result in a membrane staining of
the cells. Primary cultures of hippocampal neurons are stained
with CSF or serum of patients with an indirect immunofluores-
cence technique and the autoantibodies are visualized as surface
staining of neurons. In the IP, autoantibodies that are present in
serum of patients bind to a specific antigen, the antigen–antibody
complex is precipitated out of solution and measured.
Most laboratories use the CBA for the diagnosis of neuronal
cell surface autoantibodies, which is a highly sensitive and specific
assay but bears the disadvantage that new autoantibodies are not
detected. The TBA provides an excellent screeningmethod, which
detects most of the currently known neuronal cell surface autoan-
tibodies (with some limitations for theGlyR- andD2R-antibodies)
and can reveal new autoantibodies. To reach a maximum of sensi-
tivity and specificity, a combination of TBA as screening method
and CBA as confirmatory test may be considered (Figure 1A).
Staining of hippocampal neurons and IP ismainly used in research
but may be helpful in selected individual cases (e.g., in samples
positive in TBA but negative in CBA to characterize and ascertain
that the patient’s autoantibodies recognize a yet to be identified
cell surface antigen).
Detection of Antibodies and Interpretation of
Results
The sensitivity and specificity of serum and CSF testing has only
been investigated in a few AIE, mainly anti-NMDAR encephalitis.
While at the time of diagnosis of this disease autoantibodies are
always present in CSF, the serum can be negative in up to 14%
of patients, suggesting that serum examination alone may be
insufficient to exclude AIE (2). On the other hand, the determi-
nation of autoantibodies only in serum carries the risk of diag-
nostic errors, due to false interpretations regardless of whether
the CBA is performed with live or fixed cells. For example, a
recent case report described a patient that for more than 1 year
was considered to have anti-NMDAR encephalitis based on a
positive test in serum (CSF was not tested). When studied for
FIGURE 1 | Diagnosis of neuronal cell surface autoantibodies and
overlapping syndromes. Algorithmic approach for the diagnosis of neuronal
cell surface autoantibodies (A) most of the currently known autoantibodies
show an intensive neuropil staining in the hippocampus. The autoantibodies
are subsequently characterized on HEK293 cells transfected with the antigen
of interest (red: commercial antibody against the transfected antigen, green:
patient’s serum with autoantibodies to the transfected antigen, blue: nuclear
staining with DAPI). If all currently available cell-based assays remain negative
(red: commercial antibody against the transfected antigen, green: patient’s
serum without autoantibodies to the transfected antigen; blue: nuclear
staining with DAPI) the sample may be stained on live hippocampal neurons.
Glycin receptor- and D2R-antibodies may not be detectable by
immunohistochemistry and should be tested directly with cell-based assays.
Overlapping syndrome of anti-NMDAR encephalitis and neuromyelitis optica.
(B) Identification of NMDAR-antibodies, aquaporin-4 (AQP-4), or both
autoantibodies on tissue-based assay (TBA) showing the hippocampus
(A), the dentate gyrus of hippocampus [(B), enlarged from (A)], and cerebellar
cortex (C). Examples of patients with autoantibodies targeting only the
NMDAR (neuropil staining in hippocampus, dot-like staining in granular layer
of cerebellar cortex), only the AQP-4 (mild neuropil staining in hippocampus,
staining of glia limitans perivascularis, and reticular staining of granular layer of
cerebellar cortex), and both, NMDAR and AQP-4 (strong neuropil staining in
hippocampus, staining of glia limitans perivascularis, reticular staining of
granular layer of cerebellar cortex). Magnification: (A): 20, (B,C): 100.
a second opinion, the clinical history and examination were not
characteristic of anti-NMDAR encephalitis and her serum and
CSF was negative for NMDAR-antibodies. She was eventually
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diagnosed with narcolepsy–cataplexy (11). Other problems with
serum testing alonewere demonstrated by a study using a liveCBA
showing that 23% of patients with serum antibodies did not have
anti-NMDARencephalitis (12). These problems donot occurwith
CSF analysis; when antibodies are identified in CSF, the patients
have or have had anti-NMDAR encephalitis or a HSV-induced
AIE (13). The experience with other autoantibodies to synaptic
proteins is limited but seems to be similar; for example, all patients
with encephalitis with GABA(A)R-antibodies in CSF show a sim-
ilar syndrome characterized by prominent and refractory seizures
and cortical–subcortical FLAIR MRI abnormalities; however, if
antibodies are only found in serum, the variety of symptoms is
more extensive, questioning if there is a real association (opso-
clonus, stiff-person syndrome, among others). In contrast, LGI1-
antibodies seem to be more prevalent in serum (although most
patients have also CSF autoantibodies). Overall, these findings
suggest that (1) physicians should know about the autoantibody-
syndrome association, (2) not all autoantibodies have the same
degree of sensitivity and specificity for AIE, (3) to minimize
errors of interpretation andmisleading diagnoses, all patients with
encephalitis should have the serum and CSF tested not only for
routine studies (proteins, glucose, cells, and PCR for exclusion of
viruses) but also for autoantibodies.
Consecutive dilution steps of serum or CSF in TBA or CBA
can be used to determine autoantibody titers (the endpoint where
staining is still visible is indicated as the respective titer). The
relation between autoantibody titers, relapses, and outcome was
extensively investigated for anti-NMDAR encephalitis (2). For
example, it has been shown that high autoantibody titers were
associated with a poorer outcome or the presence of a teratoma.
In contrast, a rapid decrease of CSF autoantibody titers within the
firstmonth of disease associatedwith a better prognosis. However,
for the individual patient, autoantibody titers have limited value
to guide treatment decisions, but may be helpful in instances such
as determination of an active disease in patients with prolonged
clinical course or assessment of relapses. For these purposes, CSF
autoantibody titers were found to correlate better with the course
of the disease than serum titers.
A recent study characterized CXCL13 as a potential biomarker
for anti-NMDAR encephalitis. The CXCL13 is a cytokine pro-
duced by plasma cells and monocytes/macrophages. Seventy per-
cent of patients with new onset of anti-NMDAR encephalitis
had elevated CXCL13 levels in the CSF. Prolonged elevation of
CSF CXCL13 (4–6weeks) was an indicator of limited response
to therapy suggesting that these patients could be candidates for
more aggressive immunotherapy (14).
Trigger for Autoimmune Encephalitis
The CNS is an immune-privileged organ, protected by the
blood–brain barrier. Recognition of a specific antigen during
immune surveillance results in the activation of inflammatory
cells and release of inflammatory cytokines and chemokines that
alter tissue barrier and initiate inflammation. Antigens such as
neuronal membrane antigens do not activate the immune sys-
tem under physiological conditions, but if activation is induced
elsewhere, they can become targets for an autoimmune attack.
A number of mechanisms were identified that could account for
breaking immune tolerance in AIE (Table 1).
Tumors as Trigger for AIE
One possible trigger factor of AIE is the presence of a sys-
temic tumor that expresses the neuronal antigen and studies have
identified the expression of the targeted receptor subunit in the
tumors of patients with anti-NMDAR, AMPAR, and GABA(B)R
encephalitis (1, 5, 7). The hypothesis is that the systemic expres-
sion of these neuronal antigens initiates an immune response that
is subsequently misdirected against the brain.
Infection as Trigger for AIE
Around 20% of patients with herpes simplex virus encephali-
tis (HSVE) have relapsing symptoms without evidence for viral
reactivation (negative virus PCR in CSF, no new necrotic lesions
in the MRI, and no response to anti-viral treatment). These
episodes often manifest as choreic-like movements (chorea, oro-
facial dyskinesias, dystonia, or ballismus) accompanied by behav-
ioral changes and were considered as immune-mediated. Recent
studies found autoantibodies to the NMDAR, D2R, and other cell
surface or synaptic proteins (antigens still unknown) in some of
these patients, suggesting that HSVE may be a trigger for AIE
(13). The precisemechanisms that initiate the immune response in
anti-NMDAR encephalitis post-HSVE are not entirely clear. One
possibility is molecular mimicry, in which autoantibodies gener-
ated in response to the virus cross-react with the neuronal antigen.
Another explanation could be a viral-induced lysis of infected
neurons with release of antigens in the presence of extensive
inflammatory infiltrates. In this case, it would not be surprising
that NMDAR-antibodies might be identified also in context with
other viral infections.
Other Factors
In a considerable percentage of patients with AIE, the triggering
factor remains unknown. Studies on different AIE established a
marked predominance in females, suggesting a hormonal compo-
nent of the disease although this may relate more to the known
increased rate of autoimmunity in women. Genetic determinants
likely contribute to susceptibility to autoimmunity. For example,
specific alleles of HLA-DQB1 and HLA-DRB1 were preferen-
tially found in patients with IgLON5-antibodies (10). Patients
with AIE may have a propensity for autoimmune diseases as
some have additional autoantibodies. Interestingly, anti-nuclear-,
anti-dsDNA-, anti-cardiolipin-, or anti-TPO-antibodies are often
found in serum of patients with AIE (5, 7). However, these con-
current autoantibodies are not linked to any particular neuro-
logical manifestation or syndrome and their significance remains
to be established. A recent study of patients with anti-NMDAR
encephalitis noted that some patients with AIE have inflamma-
tory demyelinating CNS disease at times with aquaporin-4- or
MOG-antibodies, occurring before, concurrent, or after the AIE
diagnosis (Figure 1B) (15). The exact frequency of co-existingAIE
and demyelinating disease is unknown as well as whether there
is an underlying relationship between the two. Oligodendrocytes
do express NMDAR but a role of NMDAR-antibodies in myelin
dysfunction has not been studied.
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Conclusion
Recent neuroimmunological studies have provided fundamen-
tal insights into disease pathogenesis of AIE and explanations
for the wide spectrum of syndromes. The mechanisms by
which autoantibodies interfere with synaptic transmission are
diverse but all share the potential reversibility of the dysfunc-
tion, explaining in part the good recovery of many patients
after immunotherapy. These disorders result in different clini-
cal phenotypes and their description has led to novel associa-
tions with other CNS diseases (e.g., psychosis, relapsing symp-
toms post-HSVE, demyelinating disease) making these patients
an interdisciplinary challenge for treating physicians. Neuronal
cell surface autoantibodies when tested appropriately are highly
sensitive and specific diagnostic markers for AIE and have impor-
tant implications for treatment decision and long-term patient
management. Recognition of the specific AIE is important as these
disorders may have different co-morbidities or associated tumors
that need to be considered in the overall management of the
patients.
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